We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Blood Test Identifies Type 2 Diabetes Risk by Analyzing DNA Changes

By LabMedica International staff writers
Posted on 07 Apr 2023

Type 2 diabetes is a medical condition that arises when the insulin produced by the pancreas fails to function properly or is inadequate. More...

This can lead to increased levels of blood sugar and subsequently, a host of health complications such as heart diseases, stroke, nerve damage, and foot problems. At present, risk assessment tools for type 2 diabetes rely on factors like age, gender, body mass index (BMI), and family history of the disease. Now, a new study indicates that by analyzing changes in the DNA present in blood samples, it is possible to significantly improve the ability to predict the likelihood of an individual developing type 2 diabetes within a decade.

Methylation is a chemical process in the body in which a small molecule called a methyl group is added to DNA. Scientists at the University of Edinburgh (Edinburgh, Scotland, UK) examined how these alterations, in combination with other risk factors, could predict the probability of developing type 2 diabetes in almost 15,000 individuals long before any symptoms appear. The researchers found that incorporating DNA methylation data along with conventional risk factors improved the prediction accuracy.

To evaluate the predictive performance, the scientists adopted a hypothetical screening scenario involving 10,000 people where one-third of them developed type 2 diabetes over ten years. The model that incorporated DNA methylation accurately classified an additional 449 individuals compared to using traditional risk factors alone. The addition or removal of these methyl groups can impact the manner in which specific molecules act in the human body. These methylation patterns can be used to monitor the aging process and disease development. These findings could potentially enable the implementation of preventative measures earlier, thus lessening the health and economic burden of type 2 diabetes.

“Similar approaches could be taken for other common diseases to generate broad health predictors from a single blood or saliva sample,” said Professor Riccardo Marioni, Principal Investigator for the study, Centre for Genomic and Experimental Medicine at the University of Edinburgh. “We are incredibly grateful for our study volunteers who make this research possible – the more people that join our study, the more precisely we can identify signals that will help delay or reduce the onset of diseases as we age.”

Related Links:
University of Edinburgh


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.